Emergent BioSolutions Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Financial Statements
The following financial statements and supplementary data are filed as a part of this Annual Report on Form 10-K in Part II, Item 8.
Report of Independent Registered Public Accounting Firm (PCAOB ID:42)
Consolidated Balance Sheets at December 31, 2025 and 2024
Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023
Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2025, 2024 and 2023
Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023
Consolidated Statement of Changes in Stockholders' Equity for the years ended December 31, 2025, 2024 and 2023
Notes to Consolidated Financial Statements
Financial Statement Schedules
Schedule II - Valuation and Qualifying Accounts for the years ended December 31, 2025, 2024 and 2023 has been filed as part of this annual report on Form 10-K. All other financial statement schedules are omitted because they are not applicable or the required information is included in the financial statements or notes thereto.
Exhibits
Those exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto and such listing is incorporated herein by reference.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
| (in millions) | Beginning Balance | Charged to Costs and Expenses | Deductions | Ending Balance |
|---|---|---|---|---|
| Prepaid expenses and other current assets allowance | $7.2 | 0.3 | (0.1) | $7.4 |
| Prepaid expenses and other current assets allowance | $7.5 | 0.7 | (1.0) | $7.2 |
| Prepaid expenses and other current assets allowance | $7.1 | 0.8 | (0.4) | $7.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.